AI assistant to help diagnose and treat urological diseases
Official title: Development of an AI-Agent for Diagnosis and Treatment of Urological Diseases
Run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT07721935 · Data updated 2026-11-12
A large language model-based AI tool called UroAgent will be developed and tested to help doctors diagnose and plan treatment for urinary stones, prostate cancer, and bladder cancer using past records and new patient data.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 2000 (estimated) |
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Academic / other |
| Locations | 3 sites (Guangzhou, Guangdong and 2 other locations) |
| Status | Recruiting |
| Started | April 1, 2025 |
| Main results expected | December 31, 2026 |
| Study ends | June 30, 2027 |
| Registry record updated | July 23, 2026 |
| Trial ID | NCT07721935 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Patients with a diagnosed urological condition who have complete clinical information, imaging data, and, if applicable, surgical videos available for model development and validation.
✕Probably not a fit
Patients with missing data or conditions outside the study scope may not experience direct benefit from the AI tool.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study builds an AI-powered assistant specialized in urology by training on 1,500 retrospective cases and validating on 500 prospective cases, totaling 2,000 cases. The AI's diagnostic and treatment recommendations will be compared with senior urologists' standards to measure accuracy, appropriateness, completeness, and safety. The evaluation will explore performance across disease subtypes and image interpretation capabilities, with all data de-identified and handled under an ethical framework and predefined analysis plan. No patient care will be altered as part of the study, and the goal is to determine if UroAgent can support consistent, high-quality urological decision-making.
Why it matters
Potential benefit: If successful, clinicians may have a reliable AI tool to assist with faster, more consistent urology decisions, potentially improving care quality.
How similar studies have gone: Previous work in medical AI for imaging and diagnosis has shown promise, but this specific urology-focused, large-language-model assistant is a relatively novel approach with exploratory validation planned.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Diagnosed with a urological disease (e.g., urinary stones, prostate cancer, bladder cancer, and other urological conditions). 2. Availability of complete clinical information, imaging data, and surgical video required for model development and validation. Exclusion Criteria: 1\. Missing clinical information, imaging data, or surgical video.
Where it's running
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China Recruiting -
Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Shantou, Guangdong, China Recruiting -
Ganzhou People's Hospital
Ganzhou, Jiangxi, China Recruiting
Study contacts
- Study coordinator: Mingzhou Dai
- Email: daimzh3@mail2.sysu.edu.cn
- Phone: +86 19924684262
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Work status and return to work after treatment for bladder, prostate, and kidney cancers and urinary stones
This project will test how treatment for bladder, prostate, or kidney cancer and procedures for urinary stones affect whether adult patients can return to work and their quality of life.
-
Personalized 3D Tumoroids from Your Tumor to Test Treatments
Researchers are using patient tumor tissue and blood to grow personalized 3D, vascularized tumoroids with autologous immune cells to help tailor treatments for kidney, bladder, and prostate cancers.
-
Irreversible Electroporation for Recurrent Pelvic Tumors
This study tests whether using irreversible electroporation (IRE) is safe and helps control recurrent pelvic tumors in adults who can’t have other local treatments.
-
SL-28 for Advanced Solid Tumours
A new allogeneic cell therapy called SL-28 is being tested in adults with advanced solid tumors to see if it is safe and can help shrink tumors.
-
Timing smartphone messages to boost activity for older cancer survivors with chronic pain
This study tests whether sending short smartphone messages at certain times can increase physical activity in older cancer survivors with chronic pain.
-
Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors
This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.